美金刚与曲唑酮对比安慰剂治疗运动神经元病(MND SMART)的安全性与有效性:3期多臂多阶段随机适应性平台试验第一周期第二阶段中期分析
MND SMART是一项在英国20家医院中心开展的3期双盲安慰剂对照多臂多阶段随机适应性平台试验,554例运动神经元病患者随机分配至美金刚、曲唑酮或安慰剂。12个月随访显示,美金刚和曲唑酮组ALS功能评分修订版(ALSFRS-R)月均变化率与安慰剂组无显著差异,均未达到继续试验的标准,生存率亦无差异。
要点
- 美金刚与曲唑酮均未改善ALS功能评分或生存,未达到预设继续标准。
- 美金刚组不良事件发生率91%,曲唑酮组90%,安慰剂组77%。
- 作者认为该结果足以支持不再进一步测试美金刚和曲唑酮。
核心结论
- 与安慰剂相比,美金刚和曲唑酮均未改善疗效结局。
- 该结果把握度充分,足以支持不再以本研究评估的剂量进一步测试曲唑酮或美金刚治疗运动神经元病。
- 多臂多阶段设计在缩短获得确定性结果所需时间、成本和参与者数量方面显示出重要益处。
研究设计与样本
- MND SMART是由研究者主导的3期双盲安慰剂对照多臂多阶段随机适应性平台试验,在英国20家医院中心招募。
- 纳入年龄大于18岁、经修订El Escorial标准确诊的肌萎缩侧索硬化、原发性侧索硬化、进行性肌萎缩或进行性延髓麻痹患者,无论疾病持续时间。
- 参与者按1:1:1随机分配至口服曲唑酮200 mg每日一次、口服美金刚20 mg每日一次或匹配安慰剂。
- 共同主要结局为临床功能(以ALSFRS-R变化率衡量)和生存。
- 2020年2月27日至2023年7月24日(第二次中期分析数据库锁定)期间,554例运动神经元病患者被随机分配至美金刚(183例[33%])、曲唑酮(185例[33%])或安慰剂(186例[34%])。
主要发现
- 主要中期分析人群为530例,其中美金刚组175例(33%)、曲唑酮组175例(33%)、安慰剂组180例(34%)。
- 12个月随访期间,ALSFRS-R月均变化率:美金刚组-0.650,曲唑酮组-0.625,安慰剂组-0.655。
- 美金刚对比安慰剂估计平均差异0.033,单侧90%CI下限-0.085,单侧p=0.36;曲唑酮对比安慰剂估计平均差异0.065,单侧90%CI下限-0.051,单侧p=0.24。
- 至少发生一次不良事件的参与者共483例:安慰剂组145例(77%),美金刚组170例(91%),曲唑酮组168例(90%)。
- 至少发生一次严重不良事件的参与者共88例:美金刚组37例(20%),曲唑酮组27例(14%),安慰剂组24例(13%);共11例严重不良事件导致治疗中止。
关键数值与推荐
- 两个单侧p值均高于10%显著性阈值,表明美金刚组和曲唑酮组均未达到继续试验的标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Motor neuron disease represents a group of progressive and incurable diseases that are characterised by selective loss of motor neurons, resulting in an urgent need for rapid identification of effective disease-modifying therapies. The MND SMART trial aims to test the safety and efficacy of promising interventions efficiently and definitively against a single contemporaneous placebo control group. We now report results of the stage two interim analysis for memantine and trazodone. METHODS: MND SMART is an investigator-led, phase 3, double-blind, placebo-controlled, multiarm, multistage, randomised, adaptive platform trial recruiting at 20 hospital centres in the UK. Individuals older than 18 years with a confirmed diagnosis of either amyotrophic lateral sclerosis classified by the revised El Escorial criteria, primary lateral sclerosis, progressive muscular atrophy, or progressive bulbar palsy, regardless of disease duration, were eligible for screening. Participants were randomised (1:1:1) to receive oral trazodone 200 mg once a day, oral memantine 20 mg once a day, or matched placebo using a computer-generated minimisation algorithm delivered via a secure web-based system. Co-primary outcome measures were clinical functioning, measured by rate of change in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R), and survival. Comparisons were conducted in four stages, with predefined criteria for stopping at the end of stages one and two. We report interim analysis from the stage two results, which was done when 100 participants per group (excluding long survivors, defined as >8 years since diagnosis at baseline) completed a minimum of 12 months of follow-up for the candidate investigational medicinal products. The trial is registered on the European Clinical Trials Registry, 2019-000099-41, and ClinicalTrials.gov, NCT04302870, and is ongoing. FINDINGS: Between Feb 27, 2020, and July 24, 2023 (database lock for interim analysis two), 554 people with a motor neuron disease were randomly allocated to memantine (183 [33%]), trazodone (185 [33%]), or placebo (186 [34%]). The primary interim analysis population comprised 530 participants, of whom 175 (33%) had been allocated memantine, 175 (33%) had been allocated trazodone, and 180 (34%) had been allocated placebo. Over 12 months of follow-up, the mean rate of change per month in ALSFRS-R was -0·650 for memantine, -0·625 for trazodone, and -0·655 for placebo (memantine versus placebo estimated mean difference 0·033, one-sided 90% CI lower level -0·085; one-sided p=0·36; trazodone vs placebo: 0·065, -0·051; one-sided p=0·24). The one-sided p values were both above the significance threshold of 10%, indicating that neither memantine nor trazodone groups met the criteria for continuation. There were 483 participants with at least one adverse event (145 [77%] on placebo, 170 [91%] on memantine, and 168 [90%] on trazodone). There were 88 participants with at least one serious adverse event (37 [20%] on memantine, 27 [14%] on trazodone, and 24 [13%] on placebo). A total of 11 serious adverse event led to treatment discontinuation. There was no survival difference between comparisons, with 49 deaths in the memantine group, 52 deaths in the trazodone group, and 48 deaths in the placebo group. INTERPRETATION: Neither memantine nor trazodone improved efficacy outcomes compared with placebo. This result is sufficiently powered to warrant no further testing of trazodone or memantine in motor neuron disease at the doses evaluated in this study. The multiarm multistage design shows important benefits in reducing the time, cost, and participant numbers to reach a definitive result. FUNDING: The Euan MacDonald Centre, MND Scotland, My Name'5 Doddie Foundation, and Baillie Gifford.
引用
- Pal S, Chataway J, Swingler R, et al. Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial. Lancet Neurol. 2024. PMID: 39307154. doi:10.1016/S1474-4422(24)00326-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。